NBTX
Nanobiotix S.A.
NASDAQ · Healthcare · Biotechnology · FR
$38.80
−3.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 22.5M | 29.6M | (7.2M) | 36.2M | 4.8M |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | 22.5M | 29.6M | (7.2M) | 36.2M | 4.8M |
| Operating Expenses | |||||
| R&D Expense | 63.7M | 23.1M | 40.5M | 38.4M | 32.6M |
| SG&A Expense | 40.7M | 20.2M | 20.5M | 22.0M | 17.9M |
| General & Admin Expense | 8.9M | 20.2M | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (2.7M) | (2.9M) | 134.0K | 2.5M | 985.0K |
| Total Operating Expenses | 101.7M | 40.5M | 61.2M | 63.0M | 51.5M |
| Cost and Expenses | 101.7M | 40.5M | 61.2M | 63.0M | 51.5M |
| Operating Income (EBIT) | (79.2M) | (10.8M) | (68.4M) | (26.8M) | (46.7M) |
| Non-Operating | |||||
| Interest Income | 985.0K | 985.0K | 2.6M | 1.2M | 256.0K |
| Interest Expense | 10.4M | 10.4M | 8.1M | 8.0M | 5.8M |
| Net Interest Income | (9.4M) | (9.4M) | (5.5M) | (6.8M) | (5.6M) |
| Other Non-Op Income/Expense | (12.8M) | (13.1M) | 361.0K | (12.8M) | (10.3M) |
| Non-Operating Income (excl Interest) | 2.6M | 2.7M | (134.0K) | (2.5M) | (985.0K) |
| EBT (Pre-Tax Income) | (92.0M) | (24.0M) | (68.0M) | (39.6M) | (57.0M) |
| Income Tax Expense | 104.0K | 3.0K | 101.0K | 120.0K | 10.0K |
| Bottom Line | |||||
| Net Income | (92.1M) | (24.0M) | (68.1M) | (39.7M) | (57.0M) |
| Earnings from Cont. Ops | (92.1M) | (24.0M) | (68.1M) | (39.7M) | (57.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (92.1M) | (24.0M) | (68.1M) | (39.7M) | (57.0M) |
| Per Share | |||||
| Basic EPS | ($1.94) | ($0.50) | ($1.44) | ($1.08) | ($1.64) |
| Diluted EPS | ($1.94) | ($0.50) | ($1.44) | ($1.08) | ($1.64) |
| Revenue Per Share | $0.47 | $0.62 | ($0.15) | $0.99 | $0.14 |
| Shares | |||||
| Basic Shares Outstanding | 47.8M | 47.8M | 47.3M | 36.8M | 34.9M |
| Diluted Shares Outstanding | 47.8M | 47.8M | 47.3M | 36.9M | 34.9M |
| Profitability Metrics | |||||
| EBITDA | (79.2M) | (12.1M) | (67.7M) | (23.7M) | (44.2M) |
| D&A | 2.6M | 1.5M | 592.0K | 551.0K | 1.5M |
| EBIT | (81.8M) | (13.6M) | (68.3M) | (24.2M) | (45.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025